riluzole

Summary

Summary: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Top Publications

  1. ncbi Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
    R G Miller
    Department of Neurology, California Pacific Medical Center, San Francisco, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 4:191-206. 2003
  2. pmc Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole
    M Banasr
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06437, USA
    Mol Psychiatry 15:501-11. 2010
  3. pmc A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma
    Dana Yip
    Division of Surgical Oncology, Department of Surgery, UMDNJ Robert Wood Johnson Medical School, USA
    Clin Cancer Res 15:3896-902. 2009
  4. pmc Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study
    Gilbert Bensimon
    Departement de Pharmacologie Clinique, Hopital de la Pitie Salpetriere, Assistance Publique Hôpitaux de Paris and UPMC University Paris 06, UMR 7087, Paris, France
    Brain 132:156-71. 2009
  5. doi The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells
    Maithao N Le
    Division of Surgical Oncology, Department of Surgery, UMDNJ Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA
    J Invest Dermatol 130:2240-9. 2010
  6. ncbi Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1
    Elena Fumagalli
    Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milan, Italy
    Eur J Pharmacol 578:171-6. 2008
  7. doi A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?
    Mark C Bellingham
    School of Biomedical Sciences, University of Queensland, Brisbane, QLD 4072, Australia
    CNS Neurosci Ther 17:4-31. 2011
  8. doi Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer
    Cecilia L Speyer
    Breast Cancer Biology Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
    Breast Cancer Res Treat 132:565-73. 2012
  9. pmc Chemical-genetic screen identifies riluzole as an enhancer of Wnt/β-catenin signaling in melanoma
    Travis L Biechele
    Howard Hughes Medical Institute, Department of Pharmacology, and Institute for Stem Cell and Regenerative Medicine, University of Washington School of Medicine, Box 357370, Seattle, WA 98195, USA
    Chem Biol 17:1177-82. 2010
  10. doi Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
    Robert G Miller
    Forbes Norris ALS Research Center, California PacificMedical Center, San Francisco, USA
    Cochrane Database Syst Rev 3:CD001447. 2012

Detail Information

Publications240 found, 100 shown here

  1. ncbi Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
    R G Miller
    Department of Neurology, California Pacific Medical Center, San Francisco, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 4:191-206. 2003
    b>Riluzole 100 mg probably prolongs survival in patients with amyotrophic lateral sclerosis by about two months and the safety of the drug is not a major concern...
  2. pmc Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole
    M Banasr
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06437, USA
    Mol Psychiatry 15:501-11. 2010
    ..Furthermore, we analyzed the effects of riluzole, a Food and Drug Administration-approved drug for the treatment of amyotrophic laterosclerosis, known to modulate ..
  3. pmc A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma
    Dana Yip
    Division of Surgical Oncology, Department of Surgery, UMDNJ Robert Wood Johnson Medical School, USA
    Clin Cancer Res 15:3896-902. 2009
    ..Furthermore, a xenograft model of melanoma treated with riluzole, an oral GRM1 blocking agent, showed decreased tumor growth compared with the untreated controls...
  4. pmc Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study
    Gilbert Bensimon
    Departement de Pharmacologie Clinique, Hopital de la Pitie Salpetriere, Assistance Publique Hôpitaux de Paris and UPMC University Paris 06, UMR 7087, Paris, France
    Brain 132:156-71. 2009
    ..We designed a double-blind randomized placebo-controlled trial of riluzole as a potential disease-modifying agent in Parkinson plus disorders (NNIPPS: Neuroprotection and Natural History ..
  5. doi The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells
    Maithao N Le
    Division of Surgical Oncology, Department of Surgery, UMDNJ Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA
    J Invest Dermatol 130:2240-9. 2010
    ..Using the glutamate-release inhibitor Riluzole or the non-competitive GRM1 antagonist BAY 36-7620 we were able to induce considerable inhibition of colony ..
  6. ncbi Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1
    Elena Fumagalli
    Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milan, Italy
    Eur J Pharmacol 578:171-6. 2008
    b>Riluzole exerts a neuroprotective effect through different mechanisms, including action on glutamatergic transmission...
  7. doi A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?
    Mark C Bellingham
    School of Biomedical Sciences, University of Queensland, Brisbane, QLD 4072, Australia
    CNS Neurosci Ther 17:4-31. 2011
    ..b>Riluzole has been used as the only approved treatment for amyotrophic lateral sclerosis since 1995, but its mechanism(s) ..
  8. doi Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer
    Cecilia L Speyer
    Breast Cancer Biology Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
    Breast Cancer Res Treat 132:565-73. 2012
    ..mGluR1 inhibitors (Riluzole or BAY36-7620) inhibited the proliferation of triple negative breast cancer cells in a time- and dose-dependent ..
  9. pmc Chemical-genetic screen identifies riluzole as an enhancer of Wnt/β-catenin signaling in melanoma
    Travis L Biechele
    Howard Hughes Medical Institute, Department of Pharmacology, and Institute for Stem Cell and Regenerative Medicine, University of Washington School of Medicine, Box 357370, Seattle, WA 98195, USA
    Chem Biol 17:1177-82. 2010
    ..This identified 44 unique compounds, including the FDA-approved drug riluzole, which is presently in clinical trials for treating melanoma...
  10. doi Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
    Robert G Miller
    Forbes Norris ALS Research Center, California PacificMedical Center, San Francisco, USA
    Cochrane Database Syst Rev 3:CD001447. 2012
    b>Riluzole is approved for the treatment of amyotrophic lateral sclerosis in most countries. Questions persist about its clinical utility because of high cost and modest efficacy.
  11. ncbi Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice
    R J Snow
    School of Health Sciences, Deakin University, Victoria, 3125, Burwood, Australia
    Neuroscience 119:661-7. 2003
    This study investigated the effects of riluzole (Ril), creatine (Cr) and a combination of these treatments on the onset and progression of clinical signs and neuropathology in an animal model of familial amyotrophic lateral sclerosis, the ..
  12. ncbi Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma
    Jin Namkoong
    Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, 164 Frelinghuysen Road, Piscataway, NJ 08854, USA
    Cancer Res 67:2298-305. 2007
    ..human melanoma cells with a GRM1 antagonist (LY367385 or BAY36-7620) or a glutamate release inhibitor (riluzole) leads to a suppression of cell proliferation as well as a decrease in levels of extracellular glutamate...
  13. ncbi Modulation of recombinant and native neuronal SK channels by the neuroprotective drug riluzole
    Ying Jun Cao
    Department of Anesthesia and Critical Care, University of Chicago, 5841 South Maryland Avenue, MC4028, Chicago, IL 60637, USA
    Eur J Pharmacol 449:47-54. 2002
    ..We used patch clamp to study the actions of the neuroprotective drug riluzole on recombinant SK2 channels expressed in HEK293 cells and native SK channels underlying the ..
  14. ncbi Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease
    Emma Hockly
    King s College London, Department of Medical and Molecular Genetics, GKT School of Medicine, 8th Floor Guy s Tower, Guy s Hospital, London SE1 9RT, UK
    Neurobiol Dis 21:228-36. 2006
    ..To further explore the therapeutic potential of the benzothiazole aggregation inhibitors, we assessed PGL-135 and riluzole in hippocampal slice cultures derived from the R6/2 mouse, confirming their ability to inhibit aggregation with ..
  15. ncbi Glutamate release inhibition ineffective in levodopa-induced motor complications
    William Bara-Jimenez
    Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Mov Disord 21:1380-3. 2006
    ..In a 3-week, double-blind, proof-of-concept study, riluzole (200 mg/day) failed to alter parkinsonian or levodopa-induced motor complication severity...
  16. pmc Increased survival and reinnervation of cervical motoneurons by riluzole after avulsion of the C7 ventral root
    Sandor Pinter
    Laboratory of Neuromorphology, Department of Ophthalmology, Faculty of General Medicine, University of Szeged, Szeged, Hungary
    J Neurotrauma 27:2273-82. 2010
    ..in very low numbers of surviving motoneurons (65 ± 8 SEM), while treatment of the injured motoneurons with riluzole resulted in high numbers of surviving motoneurons (637 ± 26 SEM)...
  17. doi Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole
    R T Owen
    Drugs Today (Barc) 48:469-78. 2012
    ..Trials with memantine and riluzole, agents with actions broadly similar to and different from ketamine on the glutamatergic system, are also ..
  18. pmc Riluzole elevates GLT-1 activity and levels in striatal astrocytes
    Marica Carbone
    King s College London, Wolfson Centre for Age Related Diseases, Guy s Campus, London SE1 1UL, UK
    Neurochem Int 60:31-8. 2012
    ..The neuroprotective compound riluzole (100 μM) upregulated GLT-1 levels and activity, through a mechanism that was not dependent on blockade of ..
  19. ncbi Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease
    Johannes Schiefer
    University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany
    Mov Disord 17:748-57. 2002
    Glutamate excitotoxicity has been suggested to contribute to the pathogenesis of Huntington's disease (HD). Riluzole is a substance with glutamate antagonistic properties that is used for neuroprotective treatment in amyotrophic lateral ..
  20. doi The effects of riluzole on neurological, brain biochemical, and histological changes in early and late term of sepsis in rats
    Hale Z Toklu
    Department of Pharmacology, Marmara University School of Pharmacy, Istanbul, Turkey
    J Surg Res 152:238-48. 2009
    ..b>Riluzole, a glutamate release inhibitor, has been shown to have neuroprotective effects in several animal models...
  21. ncbi Riluzole reduces brain lesions and improves neurological function in rats after a traumatic brain injury
    F Wahl
    Rhone Poulenc Rorer, Pharmaceuticals Discovery, Neurodegenerative Diseases Department, Vitry sur Seine, France
    Brain Res 756:247-55. 1997
    b>Riluzole (2-amino 6-trifluoromethoxy-benzothiazole) was studied in a rat model of traumatic brain injury (TBI) induced by a fluid percussion applied laterally to the right parietal cortex...
  22. ncbi Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study
    Claudia A Braz
    Movement Disorders Unit, Department of Neurology, Universidade Federal de Sao Paulo, Brazil
    Clin Neuropharmacol 27:25-9. 2004
    The objective of this study was to evaluate the effect of riluzole on dyskinesia and the duration of the ON state in patients with Parkinson disease (PD). The authors studied 16 PD patients with levodopa-induced dyskinesia...
  23. ncbi Riluzole suppresses motor cortex facilitation in correlation to its plasma level. A study using transcranial magnetic stimulation
    P Schwenkreis
    Department of Neurology, Buerkle de la Camp Platz 1, Ruhr University Bochum, BG Kliniken Bergmannsheil, 44789 Bochum, Germany
    Exp Brain Res 135:293-9. 2000
    The aim of our study was to measure the effects of the glutamate antagonist riluzole on different parameters of motor excitability, using transcranial magnetic stimulation (TMS) during 7 days of riluzole administration, and to correlate ..
  24. pmc Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury
    J Marc Simard
    Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201 1595, USA
    Exp Neurol 233:566-74. 2012
    Both glibenclamide and riluzole reduce necrosis and improve outcome in rat models of spinal cord injury (SCI)...
  25. ncbi Riluzole, neuroprotection and amyotrophic lateral sclerosis
    B C Cheah
    Prince of Wales Medical Research Institute, Barker Street, Randwick, NSW 2031, Australia
    Curr Med Chem 17:1942-199. 2010
    ..theory of ALS gave rise to the development of therapeutic approaches and ultimately clinical trials involving riluzole, initially thought to act solely as an inhibitor of glutamate release...
  26. doi Activation of TREK currents by the neuroprotective agent riluzole in mouse sympathetic neurons
    Alba Cadaveira-Mosquera
    Department of Functional Biology and Biochemistry, University of Vigo, Campus Lagoas Marcosende, 36310 Vigo, Spain
    J Neurosci 31:1375-85. 2011
    ..Whole-cell experiments revealed a riluzole-activated current (I(RIL)), transported by potassium, in mouse superior cervical ganglion (mSCG) neurons...
  27. doi The protective effect of riluzole on manganese caused disruption of glutamate-glutamine cycle in rats
    Yu Deng
    Department of Environmental Health, School of Public Health, China Medical University, Shenyang, 110001, People s Republic of China
    Brain Res 1289:106-17. 2009
    ..In addition, the effect of 21.35 micromol/kg riluzole (Na(+) channel blocker) was studied at 200 micromol/kg MnCl(2)...
  28. pmc Blockade of persistent sodium currents contributes to the riluzole-induced inhibition of spontaneous activity and oscillations in injured DRG neurons
    Rou Gang Xie
    Institute of Neuroscience, Xi Jing Hospital, The Fourth Military Medical University, Xi an, People s Republic of China
    PLoS ONE 6:e18681. 2011
    ..large-diameter fibers isolated from the compressed DRG in Sprague-Dawley rats, we show that local application of riluzole, which blocks the I(NaP), also inhibits the spontaneous activity of A-type DRG neurons in a dose-dependent manner...
  29. ncbi Sodium and calcium current-mediated pacemaker neurons and respiratory rhythm generation
    Christopher A Del Negro
    Systems Neurobiology Laboratory, Department of Neurobiology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California 90095 1763, USA
    J Neurosci 25:446-53. 2005
    ..I(NaP)-mediated bursting was voltage dependent and blocked by 20 mum riluzole (RIL). We found Ca2+ current (I(Ca))-dependent bursting in 7...
  30. ncbi A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease
    J Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin Smith 1801, Houston, TX 77030, USA
    Parkinsonism Relat Disord 8:271-6. 2002
    ....
  31. doi Riluzole normalizes early-life stress-induced visceral hypersensitivity in rats: role of spinal glutamate reuptake mechanisms
    Romain Daniel Gosselin
    Laboratory of Neurogastroenterology, Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland
    Gastroenterology 138:2418-25. 2010
    ..Because alterations in spinal non-neuronal (astrocytic) glutamate reuptake are suspected to participate in chronic pain, we asked whether such processes occur in visceral hypersensitivity...
  32. pmc Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder
    Paul Grant
    Pediatrics and Developmental Neuroscience PDN Branch, National Institute of Mental Health, Bethesda, Maryland 20892, USA
    J Child Adolesc Psychopharmacol 20:309-15. 2010
    The antiglutamatergic drug riluzole (Rilutek) is presently being used off label in the treatment of psychiatric conditions in adult patients and, increasingly, in children...
  33. doi Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins
    Ferdinando Squitieri
    Neurogenetics Unit and Centre for Rare Disease, IRCCS Neuromed, Localita Camerelle, 86077, Pozzilli, Italy
    Eur J Nucl Med Mol Imaging 36:1113-20. 2009
    ..b>Riluzole interferes with glutamatergic neurotransmission, thereby reducing excitotoxicity, enhancing neurite formation in ..
  34. pmc Inhibition of Navβ4 peptide-mediated resurgent sodium currents in Nav1.7 channels by carbamazepine, riluzole, and anandamide
    Jonathan W Theile
    Department of Pharmacology and Toxicology, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Mol Pharmacol 80:724-34. 2011
    ..Here we examined whether carbamazepine and two other sodium channel inhibitors, riluzole and anandamide, exhibit differential inhibition of resurgent currents...
  35. pmc Mechanisms underlying the early phase of spike frequency adaptation in mouse spinal motoneurones
    G B Miles
    Department of Anatomy and Neurobiology, Dalhousie University, Halifax, NS, Canada
    J Physiol 566:519-32. 2005
    ..iberiotoxin), voltage-activated Ca2+ channels (CdCl2), M-current (linopirdine) and persistent Na+ currents (riluzole) are all unnecessary for SFA...
  36. ncbi Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury
    Ozkan Ates
    Inonu University, School of Medicine, Department of Neurosurgery, Turgut Ozal Medical Center, 44069 Malatya, Turkey
    J Clin Neurosci 14:658-65. 2007
    ..study was to compare the neuroprotective effect of three sodium channel blockers-mexiletine, phenytoin and riluzole--after SCI...
  37. doi Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis
    Massimo Pieri
    Department of Neuroscience, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Exp Neurol 215:368-79. 2009
    ..Finally, Riluzole, a selective blocker of the persistent sodium current at low concentrations, decreased the firing frequency in ..
  38. ncbi Riluzole induces apoptotic cell death in human prostate cancer cells via endoplasmic reticulum stress
    Kanako Akamatsu
    Department of Anatomy and Cell Biology, Division of Life Sciences, Osaka Medical College, Takatsuki, Osaka 569 8686, Japan
    Anticancer Res 29:2195-204. 2009
    ..Ion channel modulators have been previously associated with cell proliferation and cell death in human cancer cell lines...
  39. doi Early excitability changes in lumbar motoneurons of transgenic SOD1G85R and SOD1G(93A-Low) mice
    Arnaud Pambo-Pambo
    Laboratoire de Plasticité et Physio Pathologie de la Motricité, Unité Mixte de Recherche 6196 Centre National de la Recherche Scientifique, Aix Marseille Universite, Marseille, France
    J Neurophysiol 102:3627-42. 2009
    ....
  40. pmc Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
    Swati P Aggarwal
    Neurology Clinical Trials Unit, Massachusetts General Hospital, Charlestown, MA, USA
    Lancet Neurol 9:481-8. 2010
    ..In a pilot study, lithium treatment slowed progression of amyotrophic lateral sclerosis (ALS). We aimed to confirm or disprove these findings by assessing the safety and efficacy of lithium in combination with riluzole in patients with ALS.
  41. ncbi Brain and plasma riluzole pharmacokinetics: effect of minocycline combination
    Aline Milane
    Laboratoire de Barrières et Passage des Médicaments, EA 2706, Faculty of Pharmacy, Universite Paris Sud XI, Chatenay Malabry, Chatenay Malabry, France
    J Pharm Pharm Sci 12:209-17. 2009
    ..The only drug approved is riluzole. Minocycline is an antibiotic with numerous neuroprotective properties...
  42. ncbi Lamotrigine derivatives and riluzole inhibit INa,P in cortical neurons
    Francesca Spadoni
    IRCCS Fondazione Santa Lucia, Roma, Italy
    Neuroreport 13:1167-70. 2002
    ..Two lamotrigine derivatives (sipatrigine and 202W92) and riluzole inhibited the persistent sodium current at low, therapeutic concentrations...
  43. pmc Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo
    Atif J Khan
    Department of Radiation Oncology, UMDNJ Robert Wood Johnson Medical School, Piscataway, New Jersey, USA
    Clin Cancer Res 17:1807-14. 2011
    ..human GRM1 (hGRM1) expressing melanoma cells release excess extracellular glutamate and are growth inhibited by riluzole, an inhibitor of glutamate release...
  44. ncbi Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model
    Stefan Waibel
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany
    J Neurol 251:1080-4. 2004
    ..We examined its neuroprotective effect alone and in combination with the putative glutamate release blocker riluzole in the G93A model of familial amyotrophic lateral sclerosis (fALS)...
  45. doi Microglial SK3 and SK4 currents and activation state are modulated by the neuroprotective drug, riluzole
    B S Liu
    Toronto Western Research Institute, University Health Network, MC9 417, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada
    J Neuroimmune Pharmacol 8:227-37. 2013
    ..Here, we assessed actions of the neuroprotective drug, riluzole, on two Ca(2+)- activated K channels in microglia - SK3 (KCa2.3, KCNN3) and SK4 (KCa3...
  46. pmc Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling
    Mark E McDonnell
    Fox Chase Chemical Diversity Center, Inc, 3805 Old Easton Road, Doylestown, PA 18902, USA
    Bioorg Med Chem 20:5642-8. 2012
    b>Riluzole (1) is an approved therapeutic for the treatment of ALS and has also demonstrated anti-melanoma activity in metabotropic glutamate GRM1 positive cell lines, a mouse xenograft assay and human clinical trials...
  47. doi A riluzole- and valproate-sensitive persistent sodium current contributes to the resting membrane potential and increases the excitability of sympathetic neurones
    J Antonio Lamas
    Department of Functional Biology, Faculty of Biology, Section of Physiology, University of Vigo, Lagoas Marcosende, Vigo, Spain
    Pflugers Arch 458:589-99. 2009
    ..I(NaP) was inhibited by riluzole and valproate with an IC(50) of 2.7 and 3...
  48. ncbi Interaction of the neuroprotective drug riluzole with GABA(A) and glycine receptor channels
    B Mohammadi
    Neurological Department, Medical School Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Germany
    Eur J Pharmacol 415:135-40. 2001
    b>Riluzole is used as therapeutic agent in amyotrophic lateral sclerosis...
  49. ncbi Effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis
    K Stefan
    Department of Neurology, University of Rostock, Germany
    Ann Neurol 49:536-9. 2001
    Using transcranial magnetic stimulation, the effect of riluzole (RLZ) on cortical excitability was studied in patients with amyotrophic lateral sclerosis (ALS)...
  50. pmc Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study
    Lobna Ibrahim
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Programs, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, MD, USA
    Neuropsychopharmacology 37:1526-33. 2012
    ..b>Riluzole, a glutamatergic modulator with antidepressant and synaptic plasticity-enhancing effects, could conceivably be ..
  51. pmc Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival
    Alice Y C Liu
    Department of Cell Biology and Neuroscience, Division of Life Sciences, Rutgers State University of New Jersey, Piscataway, New Jersey 08854, USA
    J Biol Chem 286:2785-94. 2011
    ..We show that the neuroprotective drug riluzole increased the amount of HSF1 in NG108-15 neuroprogenitor cells by slowing the specific turnover of HSF1 and ..
  52. ncbi The metabotropic glutamate receptor subtype 5 antagonist MPEP and the Na+ channel blocker riluzole show different neuroprotective profiles in reversing behavioral deficits induced by excitotoxic prefrontal cortex lesions
    C Risterucci
    Laboratoire de Neurobiologie de la Cognition, CNRS UMR 6155, Universite de Provence, Case C, 3 Place Victor Hugo, 13331 Marseille Cedex 3, France
    Neuroscience 137:211-20. 2006
    ..antagonist of metabotropic glutamate receptor subtype 5, and 2-amino-6-trifluoro methoxy-benzothiole (riluzole), a Na+ channel blocker exhibiting anti-glutamatergic properties, on the ibotenate-induced damage to the rat ..
  53. doi Riluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression
    Kou Takahashi
    Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4 1 1 Ogawahigashimachi, Kodaira, Tokyo 187 8553, Japan
    Behav Brain Res 216:46-52. 2011
    ..b>Riluzole, a drug currently used to slow the progression of amyotrophic lateral sclerosis (ALS), directly affects the ..
  54. ncbi Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment
    Elisabeth Andreadou
    Department of Neurology, Athens National University, Aeginition Hospital, 74, Vas Sophia s Ave, 11528 Athens, Greece
    Clin Neurol Neurosurg 110:222-6. 2008
    ..Moreover, glycine (gly) has been shown to potentiate excitatory transmission. The "antiglutamatergic" agent riluzole has been shown to prolong survival in ALS...
  55. doi Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution
    Maria Luisa Bondi
    Istituto per lo Studio dei Materiali Nanostrutturati, sez di Palermo, Consiglio Nazionale delle Ricerche, Via Ugo La Malfa 153, 90146 Palermo, Italy
    Nanomedicine (Lond) 5:25-32. 2010
    ..In this study nanoparticulate systems as drug carriers for riluzole, with sufficiently high loading capacity and small particle size, were prepared to a reach therapeutic drug level ..
  56. doi A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers
    Todd D Levine
    PNA Center for Neurologic Research, 5090 N 40th St, Phoenix, AZ 85018, USA
    Amyotroph Lateral Scler 11:514-9. 2010
    ..Twenty patients on stable doses of riluzole were enrolled. Patients received memantine, 10 mg b.i.d., for 18 months...
  57. pmc Riluzole protects against cardiac ischaemia and reperfusion damage via block of the persistent sodium current
    S Weiss
    The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia
    Br J Pharmacol 160:1072-82. 2010
    ..Here we propose a different approach, block of the persistent sodium current (INaP)...
  58. ncbi Maintenance of eupnea of in situ and in vivo rats following riluzole: a blocker of persistent sodium channels
    Walter M St-John
    Department of Physiology, Dartmouth Medical School, Dartmouth Hitchcock Medical Center, Borwell Bldg, Lebanon, NH 03756, USA
    Respir Physiol Neurobiol 155:97-100. 2007
    ..Regardless of the level of CO(2) drive, riluzole (1-10 microM), a blocker of persistent sodium channels, caused increases in the frequency and reductions in peak ..
  59. pmc Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole
    Brian P Brennan
    Biological Psychiatry Laboratory, McLean Hospital, Belmont, MA 02478, USA
    Neuropsychopharmacology 35:834-46. 2010
    Glutamatergic abnormalities may underlie bipolar disorder (BD). The glutamate-modulating drug riluzole may be efficacious in bipolar depression, but few in vivo studies have examined its effect on glutamatergic neurotransmission...
  60. ncbi Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes)
    S J Wang
    School of Medicine, Fu Jen Catholic University, 510 Chung Cheng Road, Hsin Chuang, Taipei Hsien, Taiwan 24205
    Neuroscience 125:191-201. 2004
    We have examined the effect of riluzole, a neuroprotective agent with anticonvulsant properties, on the release of endogenous glutamate from rat cerebrocortical synaptosomes using an on-line enzyme-coupled fluorometric assay...
  61. doi Enhanced endogenous type I interferon cell-driven survival and inhibition of spontaneous apoptosis by Riluzole
    Ammar Achour
    Laboratoire des Interferons Sarcolectine, Universite Paris Descartes, Centre Universitaire des Saint Pères, 45 Rue des Saints Pères 75006 Paris, France
    Virology 386:160-7. 2009
    ..In this study, we investigated the action of Riluzole (2-amino-6-trifuromethoxybenzothiazole) in HIV-1 infection...
  62. ncbi Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002)
    Margie C Zoing
    Multidisciplinary Motor Neurone Disease Service, Institute of Neurological Sciences, Prince of Wales Hospital, Sydney, New South Wales, Australia
    J Clin Neurosci 13:78-83. 2006
    b>Riluzole is the only therapy proven in clinical trials to prolong survival in patients with motor neurone disease (MND)...
  63. ncbi Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey
    T Boraud
    Basal Gang, CNRS UMR 5543, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux, Cedex, France
    Neurosci Lett 281:75-8. 2000
    The effect of riluzole administration, an antiglutamatergic compound, on the electrophysiological activity of the pallidal complex of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys is compared with those induced by ..
  64. doi Effectiveness of riluzole in suppressing spasticity in the spinal cord injured rat
    Patrick H Kitzman
    Department of Rehabilitation Sciences, The University of Kentucky, Lexington, KY 40536 0200, USA
    Neurosci Lett 455:150-3. 2009
    ..The present study examined the effectiveness of riluzole, an agent that has been shown to reduce glutamate release, in managing spasticity within the tail musculature...
  65. ncbi Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice
    T Araki
    Department of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Science and Medicine, Aoba yama, Sendai 980 8578, Japan
    Neurosci Lett 312:50-4. 2001
    The protective effects of 2-amino-6-trifluoromethoxy benzothiazole (riluzole), a Na(+) channel blocker with antiglutamatergic activity were investigated in the model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced depletion ..
  66. ncbi Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence
    Maria C Obinu
    Neurodegenerative Disease Program, Research Center of Paris, Aventis Pharma, S A Vitry sur Seine, France
    Mov Disord 17:13-9. 2002
    Our study aimed to determine whether riluzole, which has shown efficacy as a disease-modifying agent in amyotrophic lateral sclerosis (ALS), is neuroprotective in a marmoset model of Parkinson's disease (PD)...
  67. pmc Riluzole in psychiatry: a systematic review of the literature
    Carlos A Zarate
    Mark O Hatfield CRC, Bethesda, Maryland 20892, USA
    Expert Opin Drug Metab Toxicol 4:1223-34. 2008
    ..b>Riluzole, a neuroprotective agent with anticonvulsant properties approved for the treatment of amyotrophic lateral ..
  68. ncbi Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole
    Gwen Schwartz
    Toronto Western Research Institute, Division of Cell and Molecular Biology, Division of Neurosurgery, University of Toronto, Toronto, Canada
    Prog Brain Res 137:177-90. 2002
    ..This review describes the evolution of acute spinal cord injury and provides a rationale for the clinical utility of sodium channel blockers, particularly riluzole, in the management of spinal cord trauma.
  69. doi Open-label riluzole in fragile X syndrome
    Craig A Erickson
    Department of Psychiatry, Indiana University School of Medicine, James Whitcomb Riley Hospital for Children, Indianapolis, IN 46202, USA
    Brain Res 1380:264-70. 2011
    Glutamatergic dysregulation is implicated in the pathophysiology of fragile X syndrome (FXS). Riluzole is hypothesized to have an inhibitory effect on glutamate release, block excitotoxic effects of glutamate, and potentiate postsynaptic ..
  70. doi Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model
    Peternella S Verhave
    BU CBRN Protection, TNO Defence, Security and Safety, Lange Kleiweg 137, PO Box 45, 2280 AA Rijswijk, The Netherlands
    Neuropharmacology 62:1700-7. 2012
    ..The anti-glutamatergic compound riluzole is used as a model compound for neuroprotection...
  71. pmc Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder
    Sanjay J Mathew
    Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
    Biol Psychiatry 63:891-8. 2008
    ..spectroscopic imaging ((1)H MRSI) to examine the acute and chronic effects of the glutamate-release inhibitor riluzole on hippocampal N-acetylaspartate (NAA), a neuronal marker, in patients with generalized anxiety disorder (GAD) ..
  72. ncbi The use of the potassium channel activator riluzole to test whether potassium channels mediate the capacity of isoflurane to produce immobility
    Yilei Xing
    Department of Anesthesia and Perioperative Care, University of California, San Francisco 94110, USA
    Anesth Analg 97:1020-4, table of contents. 2003
    ..alveolar anesthetic concentration (MAC) during 4-h intrathecal or IV infusions of the nonspecific KCNK activator riluzole in 54 Sprague-Dawley rats...
  73. ncbi Protective effect of combination of sulforaphane and riluzole on glutamate-mediated excitotoxicity
    Geng Chang
    Department of Neurology, The Second Hospital of Hebei Medical University, Hebei, China
    Biol Pharm Bull 33:1477-83. 2010
    ..Some drugs, including sulforaphane (SF) and riluzole, can protect motor neuron against excitotoxicity...
  74. pmc Riluzole pharmacokinetics in young patients with spinal muscular atrophy
    Chadi Abbara
    Universite d Angers, UFR Medecine, Angers Cedex, F 49045 CHU d Angers, Service Pharmacologie Toxicologie, Angers Cedex 09, France
    Br J Clin Pharmacol 71:403-10. 2011
    The objective of the present study was to assess the pharmacokinetics of riluzole in patients with spinal muscular atrophy (SMA).
  75. ncbi Persistent sodium currents in mesencephalic v neurons participate in burst generation and control of membrane excitability
    Nanping Wu
    Department of Physiological Science, UCLA, 2859 Slichter Hall, Los Angeles, CA 90095, USA
    J Neurophysiol 93:2710-22. 2005
    ..04 s, tau(recov) = 2.21 s). Riluzole (< or =5 microM) substantially reduced I(NaP), membrane resonance, postinhibitory rebound (PIR), and ..
  76. ncbi Open-label trial of riluzole in generalized anxiety disorder
    Sanjay J Mathew
    Department of Biological Psychiatry, New York State Psychiatric Institute, USA
    Am J Psychiatry 162:2379-81. 2005
    There is a need to identify novel pharmacotherapies for anxiety disorders. The authors examined the safety and efficacy of riluzole, an antiglutamatergic agent, in adult outpatients with generalized anxiety disorder.
  77. ncbi Neuroprotective effect of riluzole in MPTP-treated mice
    T Araki
    Department of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Science and Medicine, Aoba yama, Sendai 980 8578, Japan
    Brain Res 918:176-81. 2001
    The neuroprotective effects of riluzole, a Na(+) channel blocker with antiglutamatergic activity, and MK-801, a blocker of N-methyl-D-aspartate (NMDA) receptors, were compared in the model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (..
  78. pmc The fraction of activated N-methyl-D-aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole
    G Rammes
    Clinical Neuropharmacology, Max Planck Institute of Psychiatry, Kraepelinstrasse 2, 80804, Munich, Germany
    J Neural Transm 115:1119-26. 2008
    ..contributing to postsynaptic events in the presence of therapeutically relevant concentrations of the GRI riluzole (1 microM) using an in vitro hippocampal slice preparation...
  79. doi Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats
    Wojciech Zgrajka
    Department of Toxicology, Institute of Agricultural Medicine, Lublin, Poland
    Epilepsy Res 88:269-74. 2010
    In this study we investigated the effectiveness of two antiepileptic drugs: riluzole and topiramate against pilocarpine-induced seizures, which are considered to be a model of intractable epilepsy commonly used to investigate the ..
  80. pmc Intrinsic spontaneous activity and subthreshold oscillations in neurones of the rat dorsal column nuclei in culture
    Antonio Reboreda
    Section of Physiology, Department of Functional Biology, Faculty of Sciences, University of Vigo, Lagoas Marcosende, 36200 Vigo, Spain
    J Physiol 551:191-205. 2003
    ..The frequency of LTOs was voltage dependent and could be abolished by TTX (0.5 microM) and riluzole (30 microM), suggesting the participation of a sodium current...
  81. ncbi Ischemic spinal cord injury induced by aortic cross-clamping: prevention by riluzole
    L Lang-Lazdunski
    Department of Cardiovascular Surgery, Hopital Bichat and Xavier Bichat Medical University, Paris, France
    Eur J Cardiothorac Surg 18:174-81. 2000
    ..We investigated the effect of riluzole, an anti-glutamate drug, in a rat model of spinal cord ischemia.
  82. ncbi Blockade of morphine- and amphetamine-induced conditioned place preference in the rat by riluzole
    T M Tzschentke
    Department of Neuropharmacology, Zoological Institute, University of Tubingen, Germany
    Neurosci Lett 242:114-6. 1998
    ..The present study examined the effects of inhibition of presynaptic glutamate release by riluzole on the development of morphine- and amphetamine-induced CPP...
  83. doi Riluzole protects against glutamate-induced slowing of neurofilament axonal transport
    Alison Stevenson
    MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King s College, London, UK
    Neurosci Lett 454:161-4. 2009
    b>Riluzole is the only drug approved for the treatment of amyotrophic lateral sclerosis (ALS) but its precise mode of action is not properly understood...
  84. doi Riluzole-induced glial cell line-derived neurotrophic factor production is regulated through fibroblast growth factor receptor signaling in rat C6 glioma cells
    Mami Tsuchioka
    Division of Psychiatry and Neuroscience, Institute for Clinical Research, National Hospital Organization NHO Kure Medical Center and Chugoku Cancer Center, 3 1 Aoyama, Kure, Japan
    Brain Res 1384:1-8. 2011
    b>Riluzole is approved for the treatment of amyotrophic lateral sclerosis (ALS); however, recent accumulating evidence suggests that riluzole is also effective for the treatment of psychiatric disorders, such as mood disorders...
  85. doi Antinociceptive effect of riluzole in rats with neuropathic spinal cord injury pain
    Aldric Hama
    The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    J Neurotrauma 28:127-34. 2011
    ..b>Riluzole, an FDA-approved drug for the treatment of amyotrophic lateral sclerosis, has been demonstrated to attenuate ..
  86. doi Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial
    Sanjay J Mathew
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Neuropsychopharmacol 13:71-82. 2010
    ..v.) ketamine; (2) test the efficacy of the glutamate-modulating agent riluzole in preventing post-ketamine relapse; and (3) examine whether pretreatment with lamotrigine would attenuate ..
  87. doi Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro
    Nerijus Lamanauskas
    Neurobiology Sector and Spinal Laboratory, International School for Advanced Studies SISSA, Via Beirut 4, 34014 Trieste, Italy
    Eur J Neurosci 27:2501-14. 2008
    The neuroprotective agent riluzole is used for the symptomatic treatment of motoneuron disease, which strongly affects the brainstem nucleus hypoglossus...
  88. ncbi An open-label trial of riluzole in patients with treatment-resistant major depression
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics and the Pathophysiology Branch, Mood and Anxiety Disorders Program, NIMH, Department of Health and Human Services, NIH, Bethesda, MD 20892, USA
    Am J Psychiatry 161:171-4. 2004
    This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression.
  89. ncbi A phase 1 trial of riluzole in spinal muscular atrophy
    Barry S Russman
    Oregon Health Sciences University and Shriners Hospital for Children, Portland, OR 97201, USA
    Arch Neurol 60:1601-3. 2003
    ..b>Riluzole, a glutamate inhibitor, has been shown to slow the rate of decline in patients with amyotrophic lateral sclerosis,..
  90. ncbi Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia
    C Heurteaux
    Institut de Pharmacologie Moleculaire et Cellulaire, UMR 6097, CNRS Université de Nice Sophia Antipolis, Institut Paul Hamel, 660 route des Lucioles, Sophia Antipolis, 06560 Valbonne, France
    Neuroscience 137:241-51. 2006
    We investigated here the effects of alpha-linolenic acid and riluzole, both activators of the 2P-domain K+ channel family TREK/TRAAK, in a model of focal ischemia clinically relevant to stroke, not only assessing neuronal protection, but ..
  91. ncbi Kainate-induced currents in rat cortical neurons in culture are modulated by riluzole
    Cristina Zona
    Fisiologia Umana, Universita degli Studi di Roma Tor Vergata, 00133 Rome, Italy
    Synapse 43:244-51. 2002
    The action of the neuroprotective and anticonvulsant agent riluzole on kainate-induced currents was studied in rat cortical neurons in primary culture by using the whole-cell configuration of the patch-clamp technique...
  92. ncbi Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy
    S Zoccolella
    Department of Neurological Sciences, University of Bari, Italy
    Eur J Neurol 14:262-8. 2007
    b>Riluzole is to date the only treatment that prolongs amyotrophic lateral sclerosis (ALS) survival...
  93. pmc Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms
    Gerard Sanacora
    Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA
    Biol Psychiatry 61:822-5. 2007
    ..Recent evidence suggests that riluzole and other agents that target glutamate neurotransmission may show antidepressant activity.
  94. ncbi Riluzole in Huntington's disease: a 3-year, randomized controlled study
    G Bernhard Landwehrmeyer
    Department of Neurology, University of Ulm, Ulm, Germany
    Ann Neurol 62:262-72. 2007
    We conducted a randomized double-blind trial of riluzole in Huntington's disease to investigate the efficacy of this antiexcitotoxic drug in slowing disease progression.
  95. ncbi Delayed riluzole treatment is able to rescue injured rat spinal motoneurons
    A Nogradi
    Laboratory of Neuromorphology, Department of Ophthalmology, Faculty of General Medicine, University of Szeged, Korányi fasor 10 11, 6720 Szeged, Hungary
    Neuroscience 144:431-8. 2007
    The effect of delayed 2-amino-6-trifluoromethoxy-benzothiazole (riluzole) treatment on injured motoneurons was studied. The L4 ventral root of adult rats was avulsed and reimplanted into the spinal cord...
  96. ncbi Riluzole-induced oscillations in spinal networks
    Cedric Yvon
    Department of Physiology, University of Bern, Switzerland
    J Neurophysiol 97:3607-20. 2007
    ..Although full blockade of I(NaP) with riluzole disrupts such bursting, the present study shows that partial blockade of I(NaP) with low doses of riluzole ..
  97. doi An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder
    Paul Grant
    Pediatrics and Developmental Neuropsychiatry Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    J Child Adolesc Psychopharmacol 17:761-7. 2007
    Obsessive-compulsive disorder (OCD) in childhood is often refractory to treatment. Riluzole, a glutamate antagonist, has theoretical support as an alternative pharmacological treatment and has demonstrated possible benefit in some open-..
  98. ncbi Riluzole rescues cochlear sensory cells from acoustic trauma in the guinea-pig
    J Wang
    INSERM UMR 254 Université de Montpellier 1, Laboratoire de Neurobiologie de l audition, 71 rue de Navacelles, 34090 Montpellier, France
    Neuroscience 111:635-48. 2002
    ..Whatever the mechanisms, a common feature of noise damage to hair cells was mitochondrial alteration. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) is a neuroprotective agent that prevents apoptosis- and necrosis-..
  99. ncbi Specific regulation of rat glial cell line-derived neurotrophic factor gene expression by riluzole in C6 glioma cells
    Anne Sophie Caumont
    Laboratoire de Pharmacologie Expérimentale, Universite Catholique de Louvain, 54 10, Avenue Hippocrate 54, 1200 Bruxelles, Belgium
    J Neurochem 97:128-39. 2006
    ..We investigated the effects of the neuroprotective drug, riluzole, on the GDNF gene expression in glial cells...
  100. ncbi Riluzole slows the progression of neuromuscular dysfunction in the wobbler mouse motor neuron disease
    Takeo Ishiyama
    Sumitomo Pharmaceuticals Research Division, 1 98 Kasugadenaka 3 chome, Konohanaku, Osaka 554 0022, Japan
    Brain Res 1019:226-36. 2004
    In the wobbler mouse motor neuron disease (MND), we firstly evaluated the effect of riluzole, the only approved drug for amyotrophic lateral sclerosis, and compared it with that of brain-derived neurotrophic factor (BDNF)...
  101. ncbi Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole
    C Paillisse
    Service de Pharmacologie Clinique, Hopital de la Pitie Salpetriere, Paris, France
    Amyotroph Lateral Scler Other Motor Neuron Disord 6:37-44. 2005
    ..The study included a cohort of 2069 patients fulfilling broad entry criteria treated with riluzole. Over 100 demographic, biological, clinical and quality-of-life variables were monitored and assessed for their ..

Research Grants103 found, 100 shown here

  1. CLINICAL TRIALS FOR PEDIATRIC SPINAL MUSCULAR ATROPHY
    Susan Iannaccone; Fiscal Year: 2005
    ..The trials will be 6 month, open label using riluzole, albuterol and sodium 4-phenylbutyrate. All pediatric age groups from birth to 18 years will be included...
  2. Signal Transduction in Intrapulmonary Chemoreceptors
    STEVEN HEMPLEMAN; Fiscal Year: 2007
    ..This will be tested using TREK agonists or antagonists including riluzole, polyunsaturated fatty acids, arachidonic acid, cyclopropane, nitrous oxide, xenon, and osmotic challenges...
  3. Combination Therapy that Targets Glutamate Signaling in Melanoma
    James S Goydos; Fiscal Year: 2010
    ..Importantly, pharmacologic depletion of the GRM1 ligand, glutamate, with the glutamate antagonist Riluzole suppresses melanoma cell growth and increases apoptosis in vitro, and promotes apoptosis and reduces melanoma ..
  4. Involvement of astrocytic two-pore domain K+ channels in ischemic pathology
    Min Zhou; Fiscal Year: 2010
    ..of electrophysiological response of astrocytes to CIPNJFs by neuroprotectant and TREK-1 channel modulator riluzole and sipatrigine;3) Identify specific K2P-CIPNJF interaction mechanisms by selective silencing of astrocytic K2Ps ..
  5. Matrix metalloproteinases as biomarkers of neurodegeneration
    Veronica Shubayev; Fiscal Year: 2007
    ..e. riluzole, dizocilpine, minocycline)...
  6. A Phase 0 Trial of Riluzole in Patients with Resectable Stage III or IV Melanoma
    James Goydos; Fiscal Year: 2007
    ..Finally, a murine xenograft model of melanoma treated with Riluzole, an oral Grm1 blocking agent, showed decreased tumor growth in the treated mice compared to the untreated ..
  7. Characterization of KIFAP3, a Modifier of Survival in Sporadic ALS
    John E Landers; Fiscal Year: 2010
    ..0 months, a substantial improvement (~42%) that surpasses the magnitude of benefit of the single drug (riluzole) that is FDA approved for ALS in ALS...
  8. RILUZOLE MOA: TARGETS FOR IMPROVED NEUROPROTECTIVE DRUGS
    Ann Sluder; Fiscal Year: 2004
    ..b>Riluzole, the only drug currently approved for the treatment of ALS, provides only a modest extension of 2 to 3 months in ..
  9. Novel Therapeutic Agents for ALS
    DONALD KIRSCH; Fiscal Year: 2007
    ..b>Riluzole is the sole drug currently approved for the treatment of ALS and only extends the survival of ALS patients by 2-3 ..
  10. SK Channel Openers as Therapeutics for Cerebellar Ataxia
    Heike Wulff; Fiscal Year: 2006
    ..b>Riluzole, a FDA approved drug for the therapy of amyotrophic lateral sclerosis, has been reported to be a potent SK ..
  11. SK Channel Openers as Therapeutics for Cerebellar Ataxia
    Heike Wulff; Fiscal Year: 2007
    ..b>Riluzole, a FDA approved drug for the therapy of amyotrophic lateral sclerosis, has been reported to be a potent SK ..
  12. 2/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression
    Sanjay J Mathew; Fiscal Year: 2010
    ..This collaborative R01 investigates the safety and efficacy of the glutamate-modulating and neuroprotective agent riluzole in a randomized double-blind placebo-controlled clinical trial (RCT) in patients with treatment- resistant ..
  13. 3/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression
    Maurizio Fava; Fiscal Year: 2010
    ..This collaborative R01 investigates the safety and efficacy of the glutamate-modulating and neuroprotective agent riluzole in a randomized double-blind placebo-controlled clinical trial (RCT) in patients with treatment- resistant ..
  14. A Scientific Meeting of ALS Clinical Trials
    Hiroshi Mitsumoto; Fiscal Year: 2003
    ..Approved since 1996, Riluzole is the only drug available for ALS, but its benefit is limited...
  15. PROTON MRS STUDIES IN GENERALIZED ANXIETY DISORDER
    Sanjay Mathew; Fiscal Year: 2007
    ..A specific long-term goal is for the candidate to develop sufficient expertise in MRS to sustain valid and creative application to problems of GAD and related conditions. ..
  16. Phase III Trial of Minocycline in ALS-II Data Center
    Robert Miller; Fiscal Year: 2007
    ..The details of data management are described, including the methods for quality control, security and information technology. Finally, the analytic plan is described in full. ..
  17. MECHANISMS AND SITES OF VENTILATORY NEUROGENESIS
    WALTER ST JOHN; Fiscal Year: 1999
    ..Results will provide a basis for understanding the failure of mechanisms for ventilatory neurogenesis, in apneas of neonates and adults. ..
  18. MECHANISMS AND SITES OF VENTILATORY NEUROGENESIS
    WALTER ST JOHN; Fiscal Year: 1993
    ....
  19. MECHANISMS AND SITES OF VENTILATORY NEUROGENESIS
    WALTER ST JOHN; Fiscal Year: 2003
    ..Such information might provide insights into dysfunctions of the control of ventilation in humans, such as in "sleep apneas" or the "sudden infant death syndrome." ..
  20. QUANTITATIVE FUNCTION IN MOTOR NEURON DISEASE
    Eric Sorenson; Fiscal Year: 2004
    ..This will become increasingly important as our population ages, increasing demands for medical and social resources. ..
  21. IGF-I/ALS Trial
    Eric Sorenson; Fiscal Year: 2006
    ..Except for a very small minority of cases, the cause is unknown. The disease is incurable and only Riluzole has been proven to be effective in slowing the disease...
  22. Phase III Trial of Minocycline in ALS-II Data Center
    Robert Miller; Fiscal Year: 2006
    ..The details of data management are described, including the methods for quality control, security and information technology. Finally, the analytic plan is described in full. ..
  23. MECHANISMS AND SITES OF VENTILATORY NEUROGENESIS
    WALTER ST JOHN; Fiscal Year: 2007
    ..Such information might provide insights into dysfunctions of the control of ventilation in humans, such as in "sleep apnea" or the "sudden infant death syndrome." ..
  24. IGF-I/ALS Trial
    Eric Sorenson; Fiscal Year: 2007
    ..Except for a very small minority of cases, the cause is unknown. The disease is incurable and only riluzole has proven to be effective in slowing the disease...
  25. Glutamate Uptake & the Pathogenesis of Neuropathic Pain
    Jianren Mao; Fiscal Year: 2007
    ..abstract_text> ..
  26. Creatine Safety, Tolerability, and Efficacy in Huntington's Disease: CREST-E
    Steven Hersch; Fiscal Year: 2007
    ..A companion application is also submitted to support study coordination, data management, and biostatistical support under the auspices of the HSG (Bernard Ravina, principal investigator). ..